Review Article

Strategies for Enhancing Vaccine-Induced CTL Antitumor Immune Responses

Figure 1

Appropriate utilization and regulation of DCs in vaccine design induce a much more potent CTL antitumor immune response. (a) Tumor antigen-loading techniques activate DCs ex vivo. (b) Targeted drugs facilitate the capture of tumor antigens by DCs and the expression of costimulatory molecules and MHC-II in vivo. (c) Stimulatory adjuvants induce maturation of DCs and enhance the activation of CTLs.
605045.fig.001